Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Archana Ray"'
Publikováno v:
Journal of Anaesthesiology Clinical Pharmacology, Vol 26, Iss 3, Pp 319-322 (2010)
Externí odkaz:
https://doaj.org/article/42b9997dc1b642ef931bc976b10e399f
Autor:
Laura Qm Chow, Iris Gluck, Deepti Aurora-Garg, Jared Weiss, Ravit Geva, Ranee Mehra, Makoto Tahara, Tanguy Y. Seiwert, Jonathan D. Cheng, Joseph Paul Eder, Chia Chi Lin, Kumudu Pathiraja, Robert I. Haddad, Barbara Burtness, Hyun Cheol Chung, Archana Ray, Bhumsuk Keam, Hyunseok Kang, Kei Muro, Shilpa Gupta
Publikováno v:
British Journal of Cancer
Background Second-line treatment options for advanced head and neck squamous cell carcinoma (HNSCC) are limited. The phase Ib KEYNOTE-012 study evaluated the safety and the efficacy of pembrolizumab for the treatment of HNSCC after long-term follow-u
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6ce174c3cb8ad8ecd0593f2f3ec0e156
http://europepmc.org/articles/PMC6048158
http://europepmc.org/articles/PMC6048158
Autor:
Archana Ray*, Anjana Acharya
The transition probability for different states are found out for the isotopes of z=110.The half-life are also calculated and it is seen that the stable form of isotope is A=281 ,z=110
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4806901b1940fc9a09cdaf1c71c1142e
Autor:
Yung-Jue Bang, Hyun-Choel Chung, Veena Shankaran, Ravit Geva, Daniel Virgil Thomas Catenacci, Shilpa Gupta, Joseph Paul Eder, Raanan Berger, Edward J. Gonzalez, Archana Ray, Marisa Dolled-Filhart, Kenneth Emancipator, Kumudu Pathiraja, Jared K. Lunceford, Jonathan D. Cheng, Minori Koshiji, Kei Muro
Publikováno v:
Journal of Clinical Oncology. 33:4001-4001
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7f32ec908a280430b18fd16ee72da66c
https://doi.org/10.1200/jco.2015.33.15_suppl.4001
https://doi.org/10.1200/jco.2015.33.15_suppl.4001
Autor:
Daniel Virgil Thomas Catenacci, Veena Shankaran, Hyun Cheol Chung, Joseph Paul Eder, Edward Gonzalez, Jared Lunceford, Raanan Berger, Kumudu Pathiraja, Ravit Geva, Yung-Jue Bang, Minori Koshiji, Jonathan D. Cheng, Shilpa Gupta, Marisa Dolled-Filhart, Kenneth Emancipator, Archana Ray, Kei Muro
Publikováno v:
Journal of Clinical Oncology. 33:3-3
3 Background: Tumors use the PD-1 pathway to evade immune surveillance. Pembrolizumab, an anti-PD-1 monoclonal antibody, has shown antitumor activity in advanced cancers. We assessed the safety and efficacy of pembrolizumab in patients with advanced
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a7eebba433b5ea4103f29ead822d1ff1
https://doi.org/10.1200/jco.2015.33.3_suppl.3
https://doi.org/10.1200/jco.2015.33.3_suppl.3